Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 173

1.

Added value of plasma metabolomics to describe maternal effects in rat maternal and prenatal toxicity studies.

Keller J, Mellert W, Sperber S, Kamp H, Jiang X, Fabian E, Herold M, Walk T, Strauss V, van Ravenzwaay B.

Toxicol Lett. 2018 Nov 8. pii: S0378-4274(18)32043-5. doi: 10.1016/j.toxlet.2018.10.032. [Epub ahead of print]

PMID:
30414988
Free Article
2.

Impact of lincosamides antibiotics on the composition of the rat gut microbiota and the metabolite profile of plasma and feces.

Behr C, Ramírez-Hincapié S, Cameron HJ, Strauss V, Walk T, Herold M, Beekmann K, Rietjens IMCM, van Ravenzwaay B.

Toxicol Lett. 2018 Oct 15;296:139-151. doi: 10.1016/j.toxlet.2018.08.002. Epub 2018 Aug 10.

PMID:
30102961
3.

Microbiome-related metabolite changes in gut tissue, cecum content and feces of rats treated with antibiotics.

Behr C, Sperber S, Jiang X, Strauss V, Kamp H, Walk T, Herold M, Beekmann K, Rietjens IMCM, van Ravenzwaay B.

Toxicol Appl Pharmacol. 2018 Sep 15;355:198-210. doi: 10.1016/j.taap.2018.06.028. Epub 2018 Jul 6.

PMID:
30008377
4.

Corrigendum to 'Embryotoxic and pharmacologic potency ranking of six azoles in the rat whole embryo culture by morphological and transcriptomic analysis' [Toxicol. Appl. Pharmacol., 322 (2017) 15-26].

Dimopoulou M, Verhoef A, Pennings J, van Ravenzwaay B, Rietjens IMCM, Piersma AH.

Toxicol Appl Pharmacol. 2018 Sep 15;355:287. doi: 10.1016/j.taap.2018.06.005. Epub 2018 Jul 3. No abstract available.

5.

Uterine adenocarcinoma in the rat induced by afidopyropen. An analysis of the lesion's induction, progression and its relevance to humans.

Van Cott A, Frericks M, Hastings C, Honarvar N, Flick B, Fabian E, van Ravenzwaay B.

Regul Toxicol Pharmacol. 2018 Jun;95:29-51. doi: 10.1016/j.yrtph.2018.02.018. Epub 2018 Mar 3.

PMID:
29510166
6.

A comparison of the embryonic stem cell test and whole embryo culture assay combined with the BeWo placental passage model for predicting the embryotoxicity of azoles.

Dimopoulou M, Verhoef A, Gomes CA, van Dongen CW, Rietjens IMCM, Piersma AH, van Ravenzwaay B.

Toxicol Lett. 2018 Apr;286:10-21. doi: 10.1016/j.toxlet.2018.01.009. Epub 2018 Jan 11.

7.

Assessment of the analgesic dipyrone as a possible (anti)androgenic endocrine disruptor.

Passoni MT, Kristensen MN, Morais RN, Woitkowiak C, Boareto AC, da Silva Amaral BA, Grechi N, Dalsenter PR, Munkboel CH, Styrishave B, Kristensen DM, Gomes C, van Ravenzwaay B, Martino-Andrade AJ.

Toxicol Lett. 2018 Mar 15;285:139-147. doi: 10.1016/j.toxlet.2017.12.021. Epub 2017 Dec 28.

PMID:
29289696
8.

Editorial: Applying 'omics technologies in chemicals risk assessment.

van Ravenzwaay B, Sauer UG, de Matos O, Poole A.

Regul Toxicol Pharmacol. 2017 Dec;91 Suppl 1:S1-S2. doi: 10.1016/j.yrtph.2017.11.017. No abstract available.

9.

Towards a generic physiologically based kinetic model to predict in vivo uterotrophic responses in rats by reverse dosimetry of in vitro estrogenicity data.

Zhang M, van Ravenzwaay B, Fabian E, Rietjens IMCM, Louisse J.

Arch Toxicol. 2018 Mar;92(3):1075-1088. doi: 10.1007/s00204-017-2140-5. Epub 2017 Dec 12.

10.

A generic Transcriptomics Reporting Framework (TRF) for 'omics data processing and analysis.

Gant TW, Sauer UG, Zhang SD, Chorley BN, Hackermüller J, Perdichizzi S, Tollefsen KE, van Ravenzwaay B, Yauk C, Tong W, Poole A.

Regul Toxicol Pharmacol. 2017 Dec;91 Suppl 1:S36-S45. doi: 10.1016/j.yrtph.2017.11.001. Epub 2017 Nov 4. Review.

11.

Adverse outcome pathways: opportunities, limitations and open questions.

Leist M, Ghallab A, Graepel R, Marchan R, Hassan R, Bennekou SH, Limonciel A, Vinken M, Schildknecht S, Waldmann T, Danen E, van Ravenzwaay B, Kamp H, Gardner I, Godoy P, Bois FY, Braeuning A, Reif R, Oesch F, Drasdo D, Höhme S, Schwarz M, Hartung T, Braunbeck T, Beltman J, Vrieling H, Sanz F, Forsby A, Gadaleta D, Fisher C, Kelm J, Fluri D, Ecker G, Zdrazil B, Terron A, Jennings P, van der Burg B, Dooley S, Meijer AH, Willighagen E, Martens M, Evelo C, Mombelli E, Taboureau O, Mantovani A, Hardy B, Koch B, Escher S, van Thriel C, Cadenas C, Kroese D, van de Water B, Hengstler JG.

Arch Toxicol. 2017 Nov;91(11):3477-3505. doi: 10.1007/s00204-017-2045-3. Epub 2017 Oct 19. Review.

PMID:
29051992
12.

Framework for the quantitative weight-of-evidence analysis of 'omics data for regulatory purposes.

Bridges J, Sauer UG, Buesen R, Deferme L, Tollefsen KE, Tralau T, van Ravenzwaay B, Poole A, Pemberton M.

Regul Toxicol Pharmacol. 2017 Dec;91 Suppl 1:S46-S60. doi: 10.1016/j.yrtph.2017.10.010. Epub 2017 Oct 14. Review.

13.

Framework for the quality assurance of 'omics technologies considering GLP requirements.

Kauffmann HM, Kamp H, Fuchs R, Chorley BN, Deferme L, Ebbels T, Hackermüller J, Perdichizzi S, Poole A, Sauer UG, Tollefsen KE, Tralau T, Yauk C, van Ravenzwaay B.

Regul Toxicol Pharmacol. 2017 Dec;91 Suppl 1:S27-S35. doi: 10.1016/j.yrtph.2017.10.007. Epub 2017 Oct 5. Review.

14.

A transcriptomic approach for evaluating the relative potency and mechanism of action of azoles in the rat Whole Embryo Culture.

Dimopoulou M, Verhoef A, Pennings JLA, van Ravenzwaay B, Rietjens IMCM, Piersma AH.

Toxicology. 2017 Dec 1;392:96-105. doi: 10.1016/j.tox.2017.09.014. Epub 2017 Sep 29.

15.

Prediction of liver toxicity and mode of action using metabolomics in vitro in HepG2 cells.

Ramirez T, Strigun A, Verlohner A, Huener HA, Peter E, Herold M, Bordag N, Mellert W, Walk T, Spitzer M, Jiang X, Sperber S, Hofmann T, Hartung T, Kamp H, van Ravenzwaay B.

Arch Toxicol. 2018 Feb;92(2):893-906. doi: 10.1007/s00204-017-2079-6. Epub 2017 Sep 30.

16.

Applying 'omics technologies in chemicals risk assessment: Report of an ECETOC workshop.

Buesen R, Chorley BN, da Silva Lima B, Daston G, Deferme L, Ebbels T, Gant TW, Goetz A, Greally J, Gribaldo L, Hackermüller J, Hubesch B, Jennen D, Johnson K, Kanno J, Kauffmann HM, Laffont M, McMullen P, Meehan R, Pemberton M, Perdichizzi S, Piersma AH, Sauer UG, Schmidt K, Seitz H, Sumida K, Tollefsen KE, Tong W, Tralau T, van Ravenzwaay B, Weber RJM, Worth A, Yauk C, Poole A.

Regul Toxicol Pharmacol. 2017 Dec;91 Suppl 1:S3-S13. doi: 10.1016/j.yrtph.2017.09.002. Epub 2017 Sep 25. Review.

17.

The challenge of the application of 'omics technologies in chemicals risk assessment: Background and outlook.

Sauer UG, Deferme L, Gribaldo L, Hackermüller J, Tralau T, van Ravenzwaay B, Yauk C, Poole A, Tong W, Gant TW.

Regul Toxicol Pharmacol. 2017 Dec;91 Suppl 1:S14-S26. doi: 10.1016/j.yrtph.2017.09.020. Epub 2017 Sep 18. Review.

18.

Intrinsic Xenobiotic Metabolizing Enzyme Activities in Early Life Stages of Zebrafish (Danio rerio).

Otte JC, Schultz B, Fruth D, Fabian E, van Ravenzwaay B, Hidding B, Salinas ER.

Toxicol Sci. 2017 Sep 1;159(1):86-93. doi: 10.1093/toxsci/kfx116.

PMID:
28903500
19.

Investigations on the dose-response relationship of combined exposure to low doses of three anti-androgens in Wistar rats.

Schneider S, Fussell KC, Melching-Kollmuss S, Buesen R, Gröters S, Strauss V, Jiang X, van Ravenzwaay B.

Arch Toxicol. 2017 Dec;91(12):3961-3989. doi: 10.1007/s00204-017-2053-3. Epub 2017 Sep 6.

20.

Regulatory accepted but out of domain: In vitro skin irritation tests for agrochemical formulations.

Kolle SN, van Ravenzwaay B, Landsiedel R.

Regul Toxicol Pharmacol. 2017 Oct;89:125-130. doi: 10.1016/j.yrtph.2017.07.016. Epub 2017 Jul 19.

Supplemental Content

Loading ...
Support Center